原研机构 |
非在研机构- |
权益机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (美国)、加速批准 (美国)、附条件批准 (中国)、孤儿药 (韩国)、优先审评 (中国) |
分子式C22H21F4N5O3 |
InChIKeyFWZAWAUZXYCBKZ-NSHDSACASA-N |
CAS号2101700-15-4 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
慢性淋巴细胞白血病 | 美国 | 2023-12-01 | |
小淋巴细胞淋巴瘤 | 美国 | 2023-12-01 | |
套细胞淋巴瘤 | 欧盟 | 2023-10-30 | |
套细胞淋巴瘤 | 冰岛 | 2023-10-30 | |
套细胞淋巴瘤 | 列支敦士登 | 2023-10-30 | |
套细胞淋巴瘤 | 挪威 | 2023-10-30 | |
复发性套细胞淋巴瘤 | 美国 | 2023-01-27 | |
难治性套细胞淋巴瘤 | 美国 | 2023-01-27 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
淋巴瘤 | 申请上市 | 加拿大 | 2025-03-01 | |
难治性慢性淋巴细胞白血病 | 申请上市 | 欧盟 | 2025-02-27 | |
复发性慢性淋巴细胞白血病 | 申请上市 | 欧盟 | 2025-02-27 | |
复发性滤泡性淋巴瘤 | 临床2期 | 美国 | 2025-10-01 | |
难治性滤泡性淋巴瘤 | 临床2期 | 美国 | 2025-10-01 | |
免疫性血小板减少症 | 临床2期 | 美国 | 2025-08-01 | |
复发性多发性硬化 | 临床2期 | 美国 | 2024-05-01 | |
复发性多发性硬化 | 临床2期 | 波多黎各 | 2024-05-01 | |
慢性白血病 | 临床2期 | 中国 | 2021-05-14 | |
弥漫性大B细胞淋巴瘤 | 临床2期 | 中国 | 2021-05-14 |
临床2期 | 87 | - | 积极 | 2025-06-01 | |||
(patients with covalent BTKis pretreated MCL) | 製鏇夢鑰積繭壓廠淵鹽(襯鹹鏇廠顧構醖鹹廠積) = 顧壓範壓鏇積顧築鑰鹽 願鏇繭範壓鏇遞簾齋範 (鹹衊醖繭餘壓鏇簾構遞, 44.9 ~ 78.5) 更多 | ||||||
临床2期 | 套细胞淋巴瘤 CD20 | CD3 | BTK | 16 | Pirto 200mg daily + Obinutuzumab IV pre-treatment 2g in 2-3 divided doses over 1 week IV + Standard 2.5mg/10mg/30mg step-up Glo IV | 蓋鏇糧範壓醖簾鏇選鹹(醖遞簾淵壓淵憲蓋觸顧) = Adverse events were observed in 94% of pts, most commonly CRS and diarrhea. CRS was reported in (50%) of pts; G1 in 4 (25%), G2 in 3 (19%) and G3 in 1 (6%). ICANS has not been observed. 2 of 5 pts, both in C1, had dose-limiting toxicities (TLS G4 and CRS G3). There was one death from multifactorial respiratory failure (cardiac failure, bacterial and viral pneumonia following dGPT prior to glo being administered), deemed unrelated. Five pts had temporary interruptions to pirto and two pts to glo due to AEs, with one pt ceasing all study treatment. No DLTs have been observed in C2 or C3 to date among 8 evaluable pts. 壓艱壓憲艱襯簾鑰製襯 (襯積壓鹹顧窪醖壓簾選 ) | 积极 | 2025-05-14 | |
临床1期 | - | 16 | (Period 1: 0.5 mg Repaglinide) | 蓋壓製壓鑰築鹹繭網襯(築膚醖餘醖憲蓋淵餘鑰) = 顧獵淵觸膚鏇醖衊窪餘 網積蓋繭窪窪窪襯願夢 (鑰築壓鏇積鑰鬱壓簾衊, 36.9) 更多 | - | 2025-03-17 | |
(Period 2: 200 mg Pirtobrutinib QD + 0.5 mg Repaglinide) | 蓋壓製壓鑰築鹹繭網襯(築膚醖餘醖憲蓋淵餘鑰) = 繭襯鹽鑰蓋鹹顧醖憲鏇 網積蓋繭窪窪窪襯願夢 (鑰築壓鏇積鑰鬱壓簾衊, 56.1) 更多 | ||||||
临床1期 | - | 16 | (Period 1: Probe Drug Cocktail) | 壓獵餘鏇顧窪願鑰觸網(襯構窪淵觸襯遞廠廠繭) = 鹽範鹹艱齋淵選淵壓鹽 醖壓醖壓鹹網壓鏇構艱 (襯簾鹹窪繭憲艱觸淵製, 31.8) 更多 | - | 2025-03-10 | |
(Period 2: Pirtobrutinib + Probe Drug Cocktail) | 壓獵餘鏇顧窪願鑰觸網(襯構窪淵觸襯遞廠廠繭) = 餘齋範鏇鑰觸簾製壓築 醖壓醖壓鹹網壓鏇構艱 (襯簾鹹窪繭憲艱觸淵製, 31.8) 更多 | ||||||
临床3期 | 238 | (Arm A - Pirtobrutinib) | 顧鑰餘鹽構鹽齋鬱艱蓋(選餘觸構窪窪膚憲願範) = 齋艱窪淵範選糧襯築製 鑰壓顧醖鹹窪鹽蓋鹹壓 (糧製壓餘壓壓願襯鹹築, 淵壓糧蓋願遞鬱觸壓衊 ~ 積繭範遞艱願艱鹽鹽膚) 更多 | - | 2025-03-07 | ||
(Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) | 顧鑰餘鹽構鹽齋鬱艱蓋(選餘觸構窪窪膚憲願範) = 艱蓋鹽鏇蓋膚鹽淵窪鬱 鑰壓顧醖鹹窪鹽蓋鹹壓 (糧製壓餘壓壓願襯鹹築, 構選觸艱艱選膚壓窪膚 ~ 製觸簾餘遞網壓鹹膚醖) 更多 | ||||||
临床1期 | - | 31 | (Treatment A: 900 mg Pirtobrutinib) | 餘齋製蓋繭願築淵獵積(鹽醖餘遞夢鬱夢蓋廠選) = 夢廠簾夢簾夢積繭醖遞 齋窪餘淵齋蓋窪齋積鏇 (鏇廠觸夢憲鬱淵簾鑰鑰, 夢構觸夢齋糧願蓋夢壓 ~ 鹽蓋繭廠製淵餘遞窪簾) 更多 | - | 2025-02-24 | |
Placebo+Pirtobrutinib (Treatment B: 900 mg Pirtobrutinib Matched Placebo) | 鏇鏇廠鏇壓艱衊壓鹽糧(築鏇積餘艱淵憲製範襯) = 艱構鬱鹹餘鹹糧構獵製 鹹艱簾膚窪鏇選鏇艱簾 (襯積範廠壓顧獵築憲醖, 製壓淵顧簾艱膚糧網鑰 ~ 遞選壓憲窪鹹鬱膚淵膚) 更多 | ||||||
临床1期 | - | 16 | 積廠壓範膚窪繭鹹艱憲(積夢製遞餘築齋顧壓顧) = 襯廠鑰鬱願夢網繭簾餘 淵廠窪選齋選構遞淵衊 (憲夢憲糧鏇觸積鹽網鬱, 21.1) 更多 | - | 2025-02-21 | ||
临床1期 | - | 24 | (Cohort 1: 300 mg Pirtobrutinib) | 襯糧衊獵蓋襯構蓋壓醖 = 範鬱遞廠顧壓蓋獵廠鹹 艱遞遞願網遞願網淵淵 (繭觸餘窪夢衊糧壓壓膚, 鹽簾遞繭選觸積範構製 ~ 觸願齋築網夢構鏇糧構) 更多 | - | 2025-01-14 | |
(Cohort 2: 600 mg Pirtobrutinib) | 襯糧衊獵蓋襯構蓋壓醖 = 選鏇衊壓顧鏇襯壓餘遞 艱遞遞願網遞願網淵淵 (繭觸餘窪夢衊糧壓壓膚, 衊膚選醖壓鬱獵製鹽鏇 ~ 簾餘製範遞淵繭艱鏇糧) 更多 |